Free Trial

PHAXIAM Therapeutics (PHXM) Competitors

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
As of 04/25/2025

PHXM vs. VRCA, XLO, SPRO, RNTX, STTK, ATNM, ATRA, RVPH, LTRN, and BLUE

Should you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Verrica Pharmaceuticals (VRCA), Xilio Therapeutics (XLO), Spero Therapeutics (SPRO), Rein Therapeutics (RNTX), Shattuck Labs (STTK), Actinium Pharmaceuticals (ATNM), Atara Biotherapeutics (ATRA), Reviva Pharmaceuticals (RVPH), Lantern Pharma (LTRN), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry.

PHAXIAM Therapeutics vs.

PHAXIAM Therapeutics (NASDAQ:PHXM) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. PHAXIAM Therapeutics' return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
PHAXIAM TherapeuticsN/A N/A N/A
Verrica Pharmaceuticals -625.06%-591.84%-141.63%

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PHAXIAM Therapeutics and PHAXIAM Therapeutics both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat PHAXIAM Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Verrica Pharmaceuticals Very Positive

Verrica Pharmaceuticals received 167 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
PHAXIAM TherapeuticsN/AN/A
Verrica PharmaceuticalsOutperform Votes
167
63.26%
Underperform Votes
97
36.74%

Verrica Pharmaceuticals has a consensus target price of $9.50, suggesting a potential upside of 1,842.34%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Verrica Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

PHAXIAM Therapeutics has higher revenue and earnings than Verrica Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A
Verrica Pharmaceuticals$7.57M5.93-$67M-$1.54-0.32

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Summary

Verrica Pharmaceuticals beats PHAXIAM Therapeutics on 8 of the 14 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHXM vs. The Competition

MetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$10.58M$120.43M$5.47B$7.82B
Dividend YieldN/A3.69%5.43%4.27%
P/E RatioN/A3.0022.3918.44
Price / Sales0.324,221.42391.41101.46
Price / CashN/A13.0238.1834.62
Price / Book0.3934.746.684.19
Net Income-$240,000.00-$90.45M$3.22B$248.05M
7 Day PerformanceN/A4.31%6.25%6.54%
1 Month PerformanceN/A-0.27%-2.70%-1.97%
1 Year PerformanceN/A90.50%16.86%4.72%

PHAXIAM Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049News Coverage
VRCA
Verrica Pharmaceuticals
4.1035 of 5 stars
$0.46
-2.0%
$9.50
+1,971.1%
-92.9%$42.10M$7.57M-0.2540Positive News
XLO
Xilio Therapeutics
3.0905 of 5 stars
$0.79
-2.0%
$4.00
+403.8%
-24.0%$41.10M$6.34M-0.4670Gap Down
SPRO
Spero Therapeutics
4.5006 of 5 stars
$0.73
-0.7%
$5.00
+587.7%
-50.3%$40.93M$27.40M10.39150Short Interest ↑
Positive News
RNTX
Rein Therapeutics
N/A$1.86
+0.5%
N/AN/A$40.91MN/A-0.609Analyst Revision
Gap Down
STTK
Shattuck Labs
2.5345 of 5 stars
$0.85
-4.7%
$7.50
+781.0%
-92.5%$40.78M$5.72M-0.56100Upcoming Earnings
Positive News
ATNM
Actinium Pharmaceuticals
1.4299 of 5 stars
$1.30
-5.8%
$7.40
+469.2%
N/A$40.56M$81,000.00-0.9430Gap Down
ATRA
Atara Biotherapeutics
4.0066 of 5 stars
$6.90
+2.4%
$17.75
+157.2%
-57.6%$40.43M$128.94M-0.27330News Coverage
Positive News
RVPH
Reviva Pharmaceuticals
2.817 of 5 stars
$0.86
+13.5%
$10.00
+1,059.2%
-71.4%$40.32MN/A-0.785Analyst Forecast
Short Interest ↑
News Coverage
LTRN
Lantern Pharma
2.4636 of 5 stars
$3.73
+8.1%
$25.00
+570.2%
-34.7%$40.23MN/A-2.1020Gap Up
BLUE
bluebird bio
2.8159 of 5 stars
$4.09
-5.8%
$44.60
+990.5%
-77.5%$40.04M$83.81M-0.11520Short Interest ↓

Related Companies and Tools


This page (NASDAQ:PHXM) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners